EUVIMEDEUVIMED entdecken
Crossref

Pentadecylic acid from Bielong Ruangan Decoction (BLRGD) inhibits hepatocellular carcinoma (HCC) cell aggressiveness through the JAK2/STAT3 pathway

Meixuan Li, Jianhong Wei, Jiacheng Jiang, Bingbing Liu, Yi Zhou, Jianping Peng, Ruoyu Wang, Guiming Deng, Kewei Sun, Yu-Nan Wu

Pathology - Research and Practice · 2026-10 · 286 · 156528

DOI: 10.1016/j.prp.2026.156528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026-10. Verfasst von Meixuan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, STAT3 Transcription Factor, Janus Kinase 2. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Education Department of Hunan Province, Hunan University, Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) represents a significant challenge in oncology, particularly in regions with high hepatitis B virus (HBV) prevalence. Traditional Chinese Medicine (TCM), with its multifaceted therapeutic approaches, offers promising avenues for HCC treatment. This study focused on Bielong Ruangan Decoction (BLRGD) and identified pentadecylic acid as a principal active compound through network pharmacological analyses. Our research demonstrated that pentadecylic acid significantly reduced the aggressiveness of HCC and HBV-related HCC cells by inhibiting cell viability, DNA synthesis, and cell migration, and by inducing apoptosis in both animal and cell models. Further analysis revealed Peroxisome Proliferator-Activated Receptor Delta (PPARD) as a crucial downstream target, with pentadecylic acid downregulating its expression. Additionally, pentadecylic acid was found to modulate the JAK2/STAT3 pathway, a key regulator in HCC progression. Collectively, our findings underscore the therapeutic potential of pentadecylic acid from BLRGD in HCC treatment, highlighting the integration of TCM into contemporary cancer management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsSTAT3 Transcription FactorJanus Kinase 2Drugs, Chinese HerbalAnimalsHumansSignal TransductionCell MovementApoptosisCell ProliferationMiceCell Line, Tumor

Stichwörter der Autor:innen

Bielong Ruangan Decoction (BLRGD)Hepatocellular carcinoma (HCC)Pentadecylic acidThe JAK2/STAT3 pathway

Substanzen

STAT3 Transcription FactorJanus Kinase 2Drugs, Chinese HerbalSTAT3 protein, humanJAK2 protein, human

Autor:innen und Institutionen

  • Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.
  • Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China. Electronic address: wufly2000@163.com.

Förderung

  • Education Department of Hunan Province
  • Hunan University
  • Hunan Provincial Natural Science Foundation

Zitieren

APA

Li, M., Wei, J., Jiang, J., Liu, B., Zhou, Y., Peng, J., Wang, R., Deng, G., Sun, K., & Wu, Y. N. (2026). Pentadecylic acid from Bielong Ruangan Decoction (BLRGD) inhibits hepatocellular carcinoma (HCC) cell aggressiveness through the JAK2/STAT3 pathway. Pathology - Research and Practice, 286, 156528. https://doi.org/10.1016/j.prp.2026.156528

Vancouver

Li M, Wei J, Jiang J, Liu B, Zhou Y, Peng J, et al. Pentadecylic acid from Bielong Ruangan Decoction (BLRGD) inhibits hepatocellular carcinoma (HCC) cell aggressiveness through the JAK2/STAT3 pathway. Pathology - Research and Practice. 2026;286:156528. doi:10.1016/j.prp.2026.156528

BibTeX
@article{Li2026,
  author = {Li, Meixuan and Wei, Jianhong and Jiang, Jiacheng and Liu, Bingbing and Zhou, Yi and Peng, Jianping and Wang, Ruoyu and Deng, Guiming and Sun, Kewei and Wu, Yu-Nan},
  title = {Pentadecylic acid from Bielong Ruangan Decoction (BLRGD) inhibits hepatocellular carcinoma (HCC) cell aggressiveness through the JAK2/STAT3 pathway},
  journal = {Pathology - Research and Practice},
  year = {2026},
  volume = {286},
  pages = {156528},
  doi = {10.1016/j.prp.2026.156528}
}
Kostenlos starten →